A European study finds hospitalisations and insufficient growth reduce health-related quality of life in childhood ...

By Sahil Pandey and Siddhi Mahatole Feb 23 (Reuters) - Gossamer Bio's experimental treatment failed to significantly improve ...

High blood pressure can damage blood vessels over time, according to the Mayo Clinic, leaving them weaker and more prone to ...

Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...

According to NBC News, Amalia, an 18-month-old toddler, had been healthy before immigration officers detained her family in December, but soon after entering custody, her condition began to decline.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Amalia, 18 months, "nearly died" at Dilley Immigration Processing Center, a lawyer for her family said in a statement to ...

As more research finds evidence of QOL benefits, pulmonologists ponder bringing new singing programs to their patients.

Louie’s ascites was treated in The Pitt until a pulmonary hemorrhage linked to liver failure caused sudden death, shifting the episode’s focus to emergency response and complications.

O’Hara’s sudden passing on January 30 at age 71 has drawn attention to a medical emergency that can unfold rapidly. What ...

Feb 23 (Reuters) - Gossamer Bio said on Monday its experimental drug for patients with a type of lung condition missed the main goal of a late-stage study, sending the drug developer's shares down 80% ...